tirzepatide and kidney issues Disease: Safety Guide Tirzepatide and Chronic Kidney Disease:

A 2023 study published in Scientific Reports found that individuals with obesity taking semaglutide or tirzepatide reported significantly fewer drinks per episode, lower odds of binge drinking, and reduced stimulative and sedative effects of alcohol compared to a control group

and Dringen, R

PlexusDx compounds semaglutide and tirzepatide through licensed 503A compounding pharmacies, which are federally regulated but create medications tailored to individual patient needs outside the standard FDA approval process

Weight loss progress varies from person to person, but as semaglutide GLP-1 helps curb hunger and support healthier eating habits, gradual changes in weight are often seen over time